Metformin ER (Metformin Extended-Release)

Metformin ER (Metformin Extended-Release) is filed as Biguanide. The sections below restate public label fields stored for this profile.

Class
Biguanide
Generic name
Metformin Extended-Release
Route
ORAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Metformin hydrochloride extended-release tablets, USP are available as: • Extended-release tablets: 500 mg white to off-white uncoated, modified capsule shaped tablets debossed with "G7" on one side and plain on other side. • Extended-release tablets: 750 mg white to off white uncoated, modified capsule shaped tablets debossed with "G8" on one side and plain on other side. Metformin Hydrochloride Extended-Release Tablets: 500 mg and 750 mg ( 3 )
Generic available
Yes
Manufacturer
Granules India Ltd
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

How it works

12.1 Mechanism of Action Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.

Boxed warning

BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin­ associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin­ associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see Dosage and Administration (2) , Contraindications (4) , Warnings and Precautions (5.1) ]. If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1) ]. WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. ( 5.1 ) • Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin­ associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. ( 5.1 ) • If lactic acidosis is suspected, discontinue Metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. ( 5.1 )

Contraindications

4 CONTRAINDICATIONS Metformin hydrochloride extended-release tablets, USP are contraindicated in patients with: Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ) [see Warnings and Precautions (5.1)]. Hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. • Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ) ( 4 , 5.1) • Hypersensitivity to metformin (4) • Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.

Common side effects

The most common adverse reactions (>5%)

Adverse reactions

The following adverse reactions are also discussed elsewhere in the labeling: Lactic Acidosis [ see Boxed Warning and Warnings and Precautions (5.1) ] Vitamin B 12 Deficiency [ see Warnings and Precautions (5.2) ] Hypoglycemia [ see Warnings and Precautions (5.3) ]

Dosage and administration

2 DOSAGE AND ADMINISTRATION NA Recommended Dosage in Adults and Pediatric Patients Aged 10 Years and Older: • Swallow Metformin hydrochloride extended-release tablets whole and never crush, cut or chew (2.2) • Starting dosage: 500 mg orally once daily with the evening meal (2.2) • Increase the dosage in increments of 500 mg weekly, up to a maximum dosage of 2,000 mg once daily with the evening meal (2.2) • Patients receiving Metformin hydrochloride immediate-release tablets may be switched to Metformin hydrochloride extended-release tablets once daily at the same total daily dosage, up to 2,000 mg once daily (2.2) Recommended Dosage in Patients with Renal Impairment •Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.4) o Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 (2.4) o Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 (2.4) o Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 (2.4) o Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 (2.4) Discontinuation for Iodinated Contrast Imaging Procedures: • Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.5) 2.2 Recommended Dosage for Metformin Hydrochloride Extended-Release Tablets in Adults and Pediatric Patients Aged 10 Years and Older With Type 2 Diabetes Mellitus • Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew. • The recommended starting dosage of metformin hydrochloride extended-release is 500 mg orally once daily with the evening meal. • Increase the dosage in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal. • If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily. • If a dose of metformin hydrochloride extended-release tablets is missed, instruct patients not to take two doses the same day and to resume their usual dose of metformin hydrochloride extended-release tablets with the next schedule dose. 2.3 Switching Between Metformin Hydrochloride Immediate-Release Tablets and Metformin Hydrochloride Extended-Release Tablets • Patients may switch between metformin hydrochloride immediate-release tablets and metformin hydrochloride extended-release tablets at the same total daily dosage. • Patients receiving metformin hydrochloride extended-release tablets who require dosages higher than 2,000 mg daily may switch to metformin hydrochloride immediate-release tablets and titrate to the maximum total daily dosage of 2,550 mg. 2.4 Recommended Dosage in Patients With Renal Impairment • Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter. • Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m 2 . • Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m 2 is not recommended. • In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit risk of continuing therapy. • Discontinue metformin hydrochloride extended-release tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m 2 [see Warnings and Precautions (5.1) ]. 2.5 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable.

Drug interactions

7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider more frequent monitoring of these patients. Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide. Drugs that Reduce Metformin Hydrochloride Extended-release Tablets Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ]. Intervention: Consider the benefits and risks of concomitant use with metformin hydrochloride extended-release tablets. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine. Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism. Intervention: Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets. Insulin Secretagogues or Insulin Clinical Impact: Coadministration of metformin hydrochloride extended-release tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia. Intervention: Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin. Drugs Affecting Glycemic Control Clinical Impact: Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. Intervention: When such drugs are administered to a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for hypoglycemia. Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. • Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring ( 7 ) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7 ) • Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake

Common questions

What is Metformin ER approved to treat?

According to its FDA label, Metformin ER (Metformin Extended-Release) is approved for: 1 INDICATIONS AND USAGE Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Metformin hydrochloride extended-release… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Metformin ER?

Metformin ER (Metformin Extended-Release) belongs to the Biguanide class of medications.

What form does Metformin ER come in?

The FDA label lists Metformin ER (Metformin Extended-Release) as: 3 DOSAGE FORMS AND STRENGTHS Metformin hydrochloride extended-release tablets, USP are available as: • Extended-release tablets: 500 mg white to off-white uncoated, modified capsule shaped tablets debossed with "G7" on one side and plain on other side. • Extended-release tablets: 750 mg white to off white uncoated, modified capsule shaped tablets debossed with "G8" on one side and plain on other side. Metformin Hydrochloride Extended-Release Tablets: 500 mg and 750 mg ( 3 ); oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Metformin ER?

Yes. A generic version of Metformin ER (Metformin Extended-Release) is available in the U.S. Ask your pharmacist about substitution.

Does Metformin ER have a Boxed Warning?

Yes. The FDA label for Metformin ER (Metformin Extended-Release) carries a Boxed Warning. Excerpt: "BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin­ associated lact…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Metformin ER cost?

Public CMS NADAC pricing for Metformin ER (Metformin Extended-Release) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Metformin ER currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Metformin ER (Metformin Extended-Release) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Metformin ER approved by the FDA?

The FDA record lists the approval date for Metformin ER (Metformin Extended-Release) as 2018-03-16.

Who makes Metformin ER?

The FDA label lists Granules India Ltd as a labeler/manufacturer of Metformin ER (Metformin Extended-Release). Multiple firms may market generics of the same molecule.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…